Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2665MR)

This product GTTS-WQ2665MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Non-small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ2665MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1397MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ5110MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Campath-1H
GTTS-WQ7617MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ11123MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ2791MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG-282
GTTS-WQ7459MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ583MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ1688MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACZ885
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW